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a b s t r a c t
Background and purpose: Mechanical thrombectomy (MT) is now well-established treatment
method for selected patients with acute ischemic stroke (AIS) and efforts are being made to
incorporate it into the systems of stroke care. Our objective is to assess the number of AIS
individuals eligible for MT in the cohort of single academic stroke center.
Methods: We retrospectively reviewed initial non-invasive vascular imaging data of AIS
patients presenting within 5 h of symptom onset for the presence of large vessel occlusion
(LVO) over 2-year period (2015–2016). Among subjects conﬁrmed with LVO: time-to-presen-
tation, premorbid functional and on-admission neurological state, site of occlusion and
initial imaging data were further assessed. Two sets of criteria based on recent trials and
recommendations were used to determine MT eligibility. The onset-to-evaluation time limit
was set to 5 h allowing ≤60 min procedure initiation delay.
Results: 895 patients with the ﬁnal diagnosis of AIS were admitted to our stroke center as the
initial treatment facility. 246 (27.5%) presented within 5 h of symptom onset and had non-
invasive imaging performed. Among those 102 (41.5%) had causative LVO. The number of
≤5 h presenting patients eligible for MT was 51 (20.7%) when applying restrictive or 80 (32.5%)
with more permissive criteria.
Conclusion: Among AIS patients, in whom onset-to-arrival time allowed to initiate the
endovascular procedure within 6 h of symptom duration, 21% were eligible for MT treatment
according to more and 33% to less restrictive criteria. It accounts for about 6% and 9% of all
AIS cases, respectively.
© 2017 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.
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Large vessel occlusion (LVO), responsible for the signiﬁcant
portion of acute ischemic strokes (AIS) [1], is associated with low
rates of recanalization and poor prognosis when treated
medically [2]. Since 2015 several randomized clinical trials
(RCTs) proving superiority of LVO treatment by mechanical
thrombectomy (MT) were published [3]. These data have led to
development of European Stroke Organization (ESO) consensus
statement [4] and American Heart Association/American Stroke
Association (AHA/ASA) guideline [5] that recommend MT as a
ﬁrst-line treatment method in a selected group of patients.
Recently, efforts are being made to implement endovascular
AIStreatmentintothehealthcaresystemsworldwide.Developing
regionalstrokecarenetworkbasedonprimaryandcomprehensive
centers, with capability of the latter to perform MT, has been
proposed [5]. In practice, organization of the AIS management
relies on the predicted demands and cost-effectiveness analyses.
Both require estimations of MT eligible patients.
Indifferently, the arrangement of national stroke care
system that includes endovascular treatment facilities in
Poland is debated. The purpose of our study is to determine the
proportion of AIS patients suitable for MT to assist this
process.
2. Materials and methods
2.1. Study population
Between January 2015 and December 2016 928 individuals with
the ﬁnal diagnosis of AIS were admitted to the single stroke
center in Rzeszów (Poland) that is offering endovascular
treatment [6]. 33 were transfers from other units (5 referred for
MT) and were excluded from this study to obtain 895-patient
cohort that had the opportunity to undergo entire reperfusion
therapy qualiﬁcation process in our department.
All subjects had initial non-contrast CT imaging and clinical
evaluation by a neurologist. When eligible, intravenous
thrombolysis (IVT) was administered (n = 201; 22.5%). According
to in-hospital stroke protocol, every acute stroke patient within
5 h of symptom onset should have CT-angiogram performed
during qualiﬁcation for reperfusion therapy unless contra-
indications for iodine contrast administration (known allergy or
renal failure). 189 (94%) out of 201 IVT-treated group had non-
invasive vascular imaging performed. When LVO was con-
ﬁrmed, endovascular treatment (EVT) eligibility was further
assessed by the endovascular treatment team (experienced
neurologist and neuroradiologist).
For this study, we reviewed all AIS initial non-invasive
vascular imaging data from the 2-year period (2015–2016)
excluding subjects with onset-to-arrival time >5 h (n = 47). 246
(27.5%) individuals were identiﬁed in this manner. There was
no emergent MR-angiography in the settings of AIS done.
2.2. Clinical and imaging data
The selected 246-patient group had their initial non-invasive
vascular imaging assessed for the presence of treatable LVO[causative occlusion of intracranial internal carotid artery
(ICA), the ﬁrst (M1), second (M2) or third (M3) segment of
middle cerebral artery (MCA), ﬁrst (A1) or second (A2) portion
of the anterior cerebral artery (ACA), dominant vertebral artery
(VA), basilar artery (BA) and ﬁrst (P1) segment of posterior
cerebral artery]. The subjects with conﬁrmed LVO had their
records reviewed. Data on onset-to-presentation time, pre-
morbid modiﬁed Rankin Scale (mRS), National Institutes of
Health Stroke Scale (NIHSS) score on admission, site of vessel
occlusion and on initial CT imaging were collected.
2.3. Eligibility criteria
We applied two sets of criteria derived from MT RCTs that were
modiﬁed to ﬁt clinical scenario. In both of them onset-to-
presentation time was limited to 5 h to allow ≤60 min of in-
hospital delay to initiate endovascular treatment. More
restrictive criteria included subjects with MCA M1 and/or
intracranial ICA occlusion with premorbid mRS ≤2, on-
admission NIHSS ≥6 and initial CT ASPECT score of more
than 5. The less stringent MT criteria encompassed cases of
the broader range of causative LVOs (intracranial ICA, M1, M2
segments of MCA, A1 and A2 portions of ACA, BA and P1
segment of PCA), lower NIHSS threshold (≥3) and higher
premorbid disability (mRS ≤3). The tandem occlusion of MCA
and ICA was not regarded as MT contraindication in neither
group.
2.4. Statistical analysis
The analysis was started by checking the normal distribution
(Shapiro–Wilk test). Quantitative variables are presented by
rate (%). Continuous variables are presented as mean  SD
(normal distribution) and as median with interquartile range
(skewed distribution).
3. Results
In 246 cases onset-to-evaluation time allowed initiation of MT
within 6 h of symptom onset and initial non-invasive vascular
imaging was available. Among those we found 102 (41.5%)
intracranial LVO. The localization of vessel occlusion and basic
characteristics of the LVO-group are shown in the Tables 1 and
2, respectively.
According to predeﬁned restrictive MT eligibility criteria, 75
subjects with M1 or terminal ICA closure were identiﬁed.
Twenty-four of them were subsequently excluded because of:
mild neurological deﬁcit (NIHSS score <6) in 3, premorbid
functional dependency (mRS>2) or unknown status in 11,
extensive early ischemic changes on initial imaging (ASPECTS
<6) in 4 and there was more than one cause in 6 cases (Fig. 1).
With this approach we found 51 (20.7%) individuals to be
eligible for endovascular treatment.
When applying less strict criteria, 97 patients with
treatment-qualifying LVO (M1, M2, A1, A2, intracranial ICA,
P1, BA) were determined. In this group, four subjects with
extensive early ischemic changes on initial imaging (ASPECTS
<6), 6 with mRS >3 or unknown, 2 with very mild baseline
deﬁcit (NIHSS <3) and other 5 with more than one exclusion
Table 1 – The localization of vessel occlusion.
Location (n = 102) n (%)
Intracranial ICA 9 (8.8%)
M1 50 (49%)
M2 12 (11.8%)
M3 3 (2.9%)
A1 1 (1%)
A2 1 (1%)
BA 5 (4.9%)
P1 3 (2.9%)
VA 2 (2%)
Tandem ICA + MCA occlusion 16 (15.7%)
Abbreviations: ICA, internal carotid artery; MCA, middle cerebral
artery; M1, ﬁrst segment of middle cerebral artery; M2, second
segment of middle cerebral artery; M3, third segment of middle
cerebral artery; BA, basilar artery; P1, ﬁrst segment of posterior
cerebral artery; VA, vertebral artery.
Table 2 – Basic characteristics of the LVO cohort.
Variable
Median age (IQR), years 79 (66–85)
Female sex, n (%) 62 (61%)
Median onset-to presentation time (IQR), min 77 (50–134)
Median NIHSS on-admission (IQR), points 15 (10–18)
Median baseline ASPECTSS (IQR), points 9 (8–10)
Intravenous thrombolysis (IVT) treatment, n (%) 77 (76%)
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potentially qualifying for MT with permissive algorithm.
4. Discussion
We found that around 40% of AIS individuals arriving within
the EVT time window might have causative LVO. It is now
proven that in this group MT is the most effective treatment
method [4,5]. Employment of further MT inclusion criteria,
however, leads to ruling out up to half of them. Our
estimations show that, depending on qualiﬁcation algorithm
used, 21 or 33% are eventually eligible for thrombectomy.
These results are consistent with the 26% given in the French
regional registry study [7]. The other single-center analysis,
assessing eligibility to each of seven recent EVT RCTs
demonstrated rates widely ranging from 3 (THRACE [8]) to
53% (MR CLEAN [9]) [10]. The higher values provided are
probably closer to real-world clinical practice, as the inclusion
criteria tend to be more restrictive in most of the trials.
As shown, the MT-eligibility rates are highly dependent on
the criteria used. The MCA and ICA occlusions are the only
targets of clot retrieval with beneﬁts of treatment unequivo-
cally proven [11]. In our cohort, it accounted for three-quarter
(n = 75/102) of causative LVOs. There is, however, some
evidence from non-randomized studies that EVT of both M2
segment of MCA [12] and basilar artery [13,14] occlusions may
result in high recanalization rates and good clinical outcomes.
Our study demonstrates that considering MT in broader range
of LVO cases (M2, A1, A2, BA, P1), could result in treating one
more patient out of ten arriving within the treatment time
widow (12%). There is recently no solid evidence to supportthis approach, but the clinical experience shows that it might
be beneﬁcial. Similarly, mild to moderate pre-stroke disability
and low baseline NIHSS scores presumably should not be
considered as an absolute contraindication to treatment,
despite there is no clear data to conﬁrm this statement [15].
Contrary to most of the other studies estimating MT
eligibility [7,10,16], we set the limit of onset-to-evaluation time
to 5 h to allow preparation of the procedure in 60 min. The
optimization of in-hospital periprocedural organization would
probably lead to more individuals treated. Employment of
advanced imaging techniques might also affect the eligibility
rates. Tissue viability assessment (CT perfusion, perfusion–
diffusion MRI) improves patient selection as the infarct and
penumbra sizes tend to correlate with functional outcomes
[17]. It would decrease the eligibility of patients arriving within
the given time limit, but some additional late-arriving
individuals could be adequate for treatment based on
penumbral size. There is currently insufﬁcient high-quality
evidence to recommend the routine usage of those imaging
modalities in the qualiﬁcation process.
According to our in-hospital stroke protocol, in the
absence of contraindications, non-invasive vessel imaging
within 5 h of AIS symptom onset is strongly recommended.
The major weakness of our work is that we cannot accurately
evaluate adherence to this point of protocol. We found that
only 27.5% of all AIS patients (n = 246/895) underwent the
examination in the given time frame. Based on our IVT
treatment data, 94% (n = 189/201) of patients qualifying for
intravenous thrombolysis had their CTA performed. It
suggests that there was probably no substantial number of
patients with the large vessel assessment omitted. Though,
our results could be slightly overestimated due to possibility
of excluding some subjects with low probability of being MT-
eligible (e.g. with mild baseline deﬁcit, high premorbid
disability or extensive ischemic changes on initial CT) from
such evaluation. It appears that the main reason for the small
number of vessel imaging performed, was exceeding the EVT
time window and not considering it as a treatment option.
Hence, the signiﬁcant amount of patients had lost their
chances for effective reperfusion treatment due to pre-
hospital delay. Reducing the onset-to-door time constitutes
the primary point of potential improvement in the stroke care
of our population. Efforts should be undertaken to solve this
problem.
Since MT has become preferred treatment method for
selected group of AIS patients, substantial re-organization of
stroke care systems is much needed. Creating regional
networks, comprising of primary and comprehensive AIS
facilities is postulated [5]. The latter, with 24/7 access to EVT,
should serve adequate population within a reasonable time
range [4,18]. Therefore, data on eligibility and cost-effective-
ness of MT are essential to provide basis for system planning
[19]. Recent Australian population-based study predicted that
7 or 13% of all AIS patients may be candidates for EVT,
depending on criteria restrictiveness [16]. It translated into
≤22 per 100 000 person-years. Similar estimations (11–22 per
100 000) were presented by Rai and colleagues within US
population [20]. Our work is not a population-based study and
the AIS cohort is not well-characterized, but with similar
criteria applied, the eligibility rates could be roughly
Fig. 1 – Acute ischemic stroke patients eligible for mechanical thrombectomy (MT) with application of two prespecified
qualification algorithms. Each patient could meet more than one exclusion criterion. Abbreviations: AIS, acute ischemic
stroke; ICA, internal carotid artery; MCA, middle cerebral artery; M1, first segment of middle cerebral artery; M2, second
segment of middle cerebral artery; BA, basilar artery; P1, first segment of posterior cerebral artery; NIHSS, National Institutes
of Health Stroke Scale; mRS, modified Rankin score; ASPECTS, Alberta Stroke Program Early CT Score.
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abovementioned analyses, which suggests that provided
data could be cautiously used for stroke care system planning
in Poland.
5. Conclusion
We found that, depending on inclusion criteria used, 21 or 33%
of our AIS patients, whose onset-to-evaluation time allows to
initiate mechanical thrombectomy within 6 h, could be eligible
for treatment. It translates into about 6 and 9% of all AIS,
respectively. It shows that substantial number of individuals is
potential candidates for endovascular treatment and efforts
should be made to achieve comparable rates in real life.Conﬂict of interest
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